Weight Management

Medical weight management in the UK has changed considerably over the past decade. Alongside long-standing options such as orlistat, clinicians now prescribe a new generation of GLP-1 and GIP receptor agonists that can support meaningful, sustained weight loss when combined with dietary and lifestyle changes. This guide explains what obesity means as a medical condition, which treatments are licensed in the UK, how NICE decides who is eligible, how the private prescription route differs from the NHS pathway, and what to expect from starting, titrating, and eventually maintaining treatment.

Understanding obesity as a medical condition

Obesity is not a lifestyle failing; it is a chronic, relapsing metabolic condition that increases the risk of type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, fatty liver disease, osteoarthritis, and several cancers. In UK clinical practice, body mass index (BMI) is still the starting point — a BMI of 30 kg/m² or above is classed as obesity, and 27.5 kg/m² or above may be used for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean family background because cardiometabolic risk begins at a lower BMI in those groups. Waist circumference, blood pressure, HbA1c and lipid profile give a fuller picture than weight alone, and many clinicians now assess a patient’s overall metabolic health rather than treating the number on the scale as the whole story.

Because appetite, satiety and energy balance are regulated by hormones such as GLP-1, GIP, leptin, ghrelin and insulin, people living with obesity are often working against a biology that actively defends a higher body weight, not against a lack of willpower. Long-standing research shows that after weight loss the body reduces resting energy expenditure and increases hunger signals — a set-point effect that helps explain why willpower alone rarely produces durable results. That is also why medication, when it is appropriate, can be genuinely useful for some patients as one part of a wider plan alongside diet, activity, sleep and behavioural support. For a deeper explanation of how the newer injectable medicines act on these appetite pathways, see how a weight-loss injection works and what a GLP-1 receptor agonist is.

It is also worth naming what obesity is not. It is not a moral issue, and it is not something a clinician can “fix” on the patient’s behalf. Treatment works best when it is a shared decision, with the patient understanding the goals of therapy, the realistic magnitude of benefit, and the trade-offs. For many people the meaningful outcome is not a target dress size but a five-to-fifteen-per-cent reduction in body weight, which is the range at which cardiometabolic risk markers, joint symptoms, sleep apnoea and fertility begin to improve substantially.

Who is eligible for treatment in the UK

The National Institute for Health and Care Excellence (NICE) sets the framework for who can be offered pharmacological weight management on the NHS. In broad terms, treatment is considered for adults with a BMI at or above a defined threshold (usually 30 kg/m², or 27 kg/m² with a weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidaemia or obstructive sleep apnoea). Lower thresholds apply for patients from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean family backgrounds, reflecting the earlier onset of cardiometabolic risk in those groups. NHS access to newer medicines is usually restricted to specialist tier-3 weight-management services, and supply has at times been rationed while manufacturing capacity catches up with global demand.

Private clinics, including UK GPhC-registered pharmacies, may prescribe within the drug’s licensed indication after a clinician review of your history, measurements and safety questionnaire. This is the route many patients take when they meet the licensed criteria but do not qualify for, or cannot access, NHS specialist services. Your clinician will advise based on your individual circumstances; medication is not appropriate if you are pregnant, planning pregnancy, breastfeeding, have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2), have a history of pancreatitis, or have certain gastrointestinal conditions such as severe gastroparesis. Interactions with other medicines — particularly insulin, sulfonylureas and oral contraceptives — will also be reviewed.

Regardless of route, a good weight-management assessment goes beyond BMI. Expect questions about eating patterns, binge episodes, mental health, previous weight-loss attempts, thyroid symptoms, sleep and family history. This context is what allows a clinician to decide whether a medicine is appropriate at all, and if so which one is likely to be the best starting point for you as an individual.

The main treatment categories

UK weight-management medicines fall into three broad groups. The GLP-1 receptor agonists mimic glucagon-like peptide-1, slowing gastric emptying and increasing satiety. This group includes Wegovy (semaglutide) as a once-weekly injection, Rybelsus as an oral semaglutide tablet, and Saxenda (liraglutide) as a once-daily injection. The dual GIP/GLP-1 receptor agonists are represented by Mounjaro (tirzepatide), which acts on two incretin pathways at once. Semaglutide vs tirzepatide compares the two, and which weight-loss injection works best for you explains how clinicians match the medicine to the patient.

The third group is the lipase inhibitors, of which orlistat (Xenical) is the licensed UK option. Orlistat blocks the absorption of about a third of dietary fat and is taken with meals; it works differently from the injectable medicines and can be a reasonable choice for patients who prefer a non-hormonal route or who are not suitable for GLP-1 therapy.

Oral versus injectable options

Injectable therapies are given as a once-weekly (semaglutide, tirzepatide) or once-daily (liraglutide) subcutaneous injection into the abdomen, thigh or upper arm using a pre-filled pen. The pens are designed to be self-administered after a brief clinician demonstration. Oral semaglutide (Rybelsus) offers a tablet route for people who prefer to avoid needles or find self-injection difficult. The two Wegovy formats are compared in is there a Wegovy pill in the UK and Wegovy pill vs Wegovy injection. Oral semaglutide requires strict fasting on an empty stomach with a small sip of water and no other food, drink or medication for 30 minutes, which suits some morning routines much better than others. This administration constraint is one of the most important factors in choosing between the two.

Choice of medicine also depends on tolerability, clinical response and, in practice, availability. Some patients try one agent and switch to another because side effects were difficult to tolerate or the response was smaller than expected. Switching is a clinical decision and involves a wash-out period and re-titration, so it is not something to do independently. Your clinician will build a picture of what your body is telling you and adjust accordingly.

The UK medical pathway — NHS vs private

The NHS route usually starts with your GP. A conversation about weight is often triggered by a related concern such as knee pain, sleep apnoea, prediabetes or fertility. Initial support in primary care includes lifestyle advice, tier-1 (community) and tier-2 (structured behavioural) weight-management programmes such as the NHS Digital Weight Management Programme, and where appropriate an onward referral to a tier-3 specialist multidisciplinary service. Tier-3 clinics offer detailed medical assessment, dietetic and psychological input, and access to prescribed pharmacotherapy and, for a small group of patients, bariatric surgery via tier-4 services. Waiting times vary substantially between regions.

The private route, including UK GPhC-registered online pharmacies, works differently. There is no NHS-style referral pathway; instead, an initial online consultation collects your medical history, current medications, weight, height and any relevant recent test results. A UK-registered prescriber reviews this information and decides whether treatment can safely and appropriately be issued within the medicine’s licence. If it can, prescriptions are dispensed by the pharmacy with clear instructions for use, monitoring intervals and safety-netting. If treatment is not appropriate, the clinician will explain why and, where relevant, signpost NHS support. The private route is faster and often more flexible, but it does not replace shared decision-making with your regular GP, particularly if you have other long-term conditions.

Dose titration, timelines and plateaus

All GLP-1 and GIP/GLP-1 medicines start at a low introductory dose and are stepped up over several weeks to reduce gastrointestinal side effects and let the body adjust. Titration schedules are set out in the British National Formulary and on the pen labelling. For tirzepatide, when to increase your Mounjaro dose outlines the typical four-week interval between steps and when clinicians may hold a dose longer. Some patients respond well to a lower maintenance dose and do not need to reach the maximum — staying on a low dose of Wegovy discusses when that is reasonable.

Appetite changes often begin within the first two to four weeks, but meaningful weight loss usually takes longer to become visible; how long it takes for Mounjaro to work gives realistic expectations. A weight plateau after several months is common and does not automatically mean the medicine has stopped working — energy expenditure adapts and dietary drift can creep in. Why am I not losing weight on Mounjaro covers the practical checks a clinician will work through, from injection technique to diet review and dose optimisation.

Realistic dose planning includes recognising that not every step needs to be taken. Product labelling defines a maximum dose, but many patients settle at an intermediate dose that gives adequate appetite regulation and tolerable side effects. Pushing to the maximum dose without a clear reason can increase side effects without proportionate benefit. Equally, if progress genuinely stalls at a lower dose after a fair trial of eight to twelve weeks, a step up is a reasonable next move, guided by weight trends and how well side effects are being tolerated. Weight trends over four-week rolling averages are more informative than day-to-day scale readings, which can swing several kilograms with hydration and bowel habit.

Side effects, safety and monitoring

The most common side effects of GLP-1 and GIP/GLP-1 therapy are gastrointestinal: nausea, reflux, constipation or loose stools, burping and reduced appetite. These are usually mild-to-moderate, most noticeable in the first week or two after starting or after each dose increase, and tend to settle as the body adjusts to the medicine’s effect on gastric emptying. Practical self-care makes a real difference: smaller, lower-fat meals, avoiding very rich or fried foods during titration, eating slowly, and keeping well hydrated. How long Mounjaro side effects last gives a typical timeline and self-care advice that applies broadly across this class.

Rare but important risks include acute pancreatitis, gallbladder disease (particularly when weight loss is rapid), and hypoglycaemia in patients also taking insulin or a sulfonylurea. Orlistat has a distinct side-effect profile centred on unabsorbed fat — loose, oily stools, faecal urgency and, over time, reduced absorption of fat-soluble vitamins A, D, E and K, which is why a general multivitamin taken away from doses is often advised. Any severe or persistent abdominal pain (particularly if radiating to the back), jaundice, or signs of dehydration warrant urgent clinical review rather than a wait-and-see approach.

Ongoing monitoring typically includes weight, blood pressure and, for patients with type 2 diabetes or pre-diabetes, HbA1c. Clinicians will also review mental wellbeing, eating patterns and any red flags such as recurrent vomiting or gallstone symptoms. A follow-up rhythm of roughly monthly during titration and every three to six months during maintenance is common. Reliable general information on obesity is available on the NHS website, and product-specific safety details are in the BNF.

Long-term maintenance and stopping treatment

Obesity is a chronic condition, and weight regain after stopping medication is common because the underlying biology of appetite regulation reasserts itself once the drug is no longer influencing incretin signalling. NICE and licensed product information support continued use when treatment is tolerated and helpful, alongside sustained dietary, activity and behavioural change. In practical terms this means treating weight-management medication in a similar frame of mind to a medicine for blood pressure or cholesterol — something you may take for years rather than for a single planned course.

Where a patient and clinician agree to stop, a gradual step-down of the dose combined with a strong maintenance plan gives the best chance of holding weight loss. A useful maintenance framework focuses on protein intake sufficient to protect lean muscle (typically 1.2–1.6 g per kilogram of body weight per day for most adults), regular resistance exercise two to three times a week, consistent sleep, and structured habits around eating times. Some patients maintain successfully on a lower ongoing dose rather than stopping altogether; this is an increasingly common pattern in UK practice.

When to seek urgent review

Contact your clinician or NHS 111 promptly if you develop severe upper abdominal pain radiating to the back, persistent vomiting, signs of dehydration, yellowing of the skin or eyes, black or bloody stools, chest pain or breathlessness, or symptoms of low blood sugar (particularly if you also take insulin or a sulfonylurea). These are not typical side effects and need same-day assessment. It is also sensible to check in with your prescriber if new or worsening depression or thoughts of self-harm develop while on treatment, or if you are planning pregnancy, since these medicines should be stopped before conception with an appropriate wash-out period agreed with your clinician.

Diet, exercise and behavioural change alongside medication

No weight-management medicine works in isolation. The clinical trials underpinning the newer GLP-1 and GIP/GLP-1 agents all included dietary and lifestyle advice as part of the intervention arm, so the results people read about include those inputs. In practical terms this means treatment works best when you actively use the reduced-appetite window to reshape how you eat, not simply eat the same food in smaller portions. A protein-forward pattern, plenty of vegetables, adequate fibre, sensible hydration and limiting ultra-processed foods will maximise both weight loss and the nutritional quality of what you do eat.

Physical activity should include both cardiovascular work — brisk walking, cycling, swimming — and resistance training two to three times a week. Resistance training is particularly important during active weight loss because it protects lean muscle mass, which in turn protects resting metabolic rate and long-term maintenance. Sleep, stress management, alcohol moderation and, for some patients, structured psychological support address the parts of eating behaviour that medication cannot reach directly.

How Farmeci fits in

Farmeci is a UK GPhC-registered online pharmacy. Our role in weight management is patient education and, where clinically appropriate, a free clinician consultation to assess whether a licensed weight-management medicine is suitable for you. We do not replace your GP or an NHS specialist weight-management service, and we work within NICE guidance and the medicine’s licence. You can browse the full weight management article library for topic-by-topic explainers, or read general wellbeing guides on sleep, stress and habit change that support any weight-management journey.